• Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, Pilar Giraldo, Manuel Pérez-Encinas, Raquel de Paz, Joaquín Martínez-López, Guiomar Bautista, Santiago Osorio, María-José Requena, Luis Palomera, María-Jesús Peñarrubia, Carmen Calle, José-Ángel Hernández-Rivas, Carmen Burgaleta, Begoña Maestro, Nuria García-Ormeña, and Juan-Luis Steegmann.
• Registro Español de Investigación y Tratamiento de Leucemia Mieloide Crónica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia], Madrid, Spain.
• Cancer Med. 2015 Jul 1; 4 (7): 995-1002.

AbstractChronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 months of therapy). The results of switching to second-generation tyrosine kinase inhibitors (2GTKIs) may contain a bias since, in the majority of these studies, patients who switch treatment due to intolerance or failure are censored or excluded. We analyzed the Spanish Registry data on switching in an intention-to-treat analysis of patients in standard clinical practice. Switching to 2GTKIs improves responses from 45% to 75% of complete cytogenetic response (CCyR) and from 15% to 45% of major molecular response (MMR) in the group without molecular response 1 (MR1) at 3 months and from 70% to 87% in CCyR and from 52% to 87% in MMR in the group with MR1. The final response rate is poorer in the group with no MR1 at 3 months. Nevertheless, the differences in the rates of response were not translated into differences in major events (transformations or deaths), and the final progression-free survival and overall survival were similar. © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

42 keywords...

hide…